Vitamin K Deficiency Bleeding

Categories: Blood diseases, Gastrointestinal diseases, Metabolic diseases

Aliases & Classifications for Vitamin K Deficiency Bleeding

MalaCards integrated aliases for Vitamin K Deficiency Bleeding:

Name: Vitamin K Deficiency Bleeding 12 15
Vitamin K Deficiency 12 54 44 70
Deficiency of Vitamin K 12 32
Vitamin K Deficiency Hemorrhagic Disease 12
Vitamin K 42


External Ids:

Disease Ontology 12 DOID:11249
ICD9CM 34 269.0
MeSH 44 D014813
NCIt 50 C99108
SNOMED-CT 67 52675005
ICD10 32 E56.1
UMLS 70 C0042880

Summaries for Vitamin K Deficiency Bleeding

MedlinePlus : 42 Vitamins are substances that your body needs to grow and develop normally. Vitamin K helps your body by making proteins for healthy bones and tissues. It also makes proteins for blood clotting. If you don't have enough vitamin K, you may bleed too much. Newborns have very little vitamin K. They usually get a shot of vitamin K soon after they are born. If you take blood thinners, you need to be careful about how much vitamin K you get. You also need to be careful about taking vitamin E supplements. Vitamin E can interfere with how vitamin K works in your body. Ask your health care provider for recommendations about these vitamins. There are different types of vitamin K. Most people get vitamin K from plants such as green vegetables, and dark berries. Bacteria in your intestines also produce small amounts of another type of vitamin K.

MalaCards based summary : Vitamin K Deficiency Bleeding, also known as vitamin k deficiency, is related to hereditary combined deficiency of vitamin k-dependent clotting factors and atrial fibrillation. An important gene associated with Vitamin K Deficiency Bleeding is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Metabolism of proteins and Response to elevated platelet cytosolic Ca2+. The drugs fluindione and Phenindione have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and breast, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A nutritional deficiency disease that is characterized by easy bleeding due to an inability to form blood clots caused by vitamin K deficiency, occurs most commonly in newborns, and has material basis in deficiency of vitamin K secondary to liver prematurity, lack of vitamin K in a breastmillk diet, largely sterile gut, malabsorption, diarrhea, chronic illness, menorrhagia, chronic kidney disease, and some medications.

Wikipedia : 73 Vitamin K deficiency bleeding (VKDB) of the newborn, previously known as haemorrhagic disease of the... more...

Related Diseases for Vitamin K Deficiency Bleeding

Diseases related to Vitamin K Deficiency Bleeding via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 606)
# Related Disease Score Top Affiliating Genes
1 hereditary combined deficiency of vitamin k-dependent clotting factors 32.6 VKORC1 GGCX
2 atrial fibrillation 31.6 VKORC1 F9 F2
3 factor x deficiency 31.5 F9 F7 F3 F2
4 protein c deficiency 31.4 SERPINC1 F9 F2
5 protein s deficiency 31.0 SERPINC1 PROS1 F3 F2
6 thrombophilia due to thrombin defect 30.9 SERPINC1 F8 F3 F2
7 factor vii deficiency 30.8 SERPINC1 F9 F8 F7 F3 F2
8 hematocele of tunica vaginalis testis 30.6 F2 AFP
9 hemophilia b 30.5 SERPINC1 F9 F8 F7 F3 F2
10 hemophilia 30.4 F9 F8 F7
11 prothrombin deficiency 30.3 SERPINC1 GGCX F9 F8 F7 F3
12 analbuminemia 30.3 F3 F2
13 antiphospholipid syndrome 30.3 SERPINC1 F3 F2
14 pseudoxanthoma elasticum 30.3 VKORC1 MGP GGCX
15 vascular disease 30.2 SERPINC1 MGP F8 F3 F2
16 mitral valve stenosis 30.1 SERPINC1 F3 F2
17 heparin-induced thrombocytopenia 30.0 SERPINC1 F3
18 lemierre's syndrome 30.0 F3 F2
19 prothrombin deficiency, congenital 30.0 SERPINC1 F2
20 active peptic ulcer disease 30.0 F7 F3 F2
21 liver cirrhosis 29.9 SERPINC1 F3 F2 AFP
22 varicose veins 29.9 SERPINC1 MGP F2
23 peripheral vascular disease 29.9 SERPINC1 F3 F2
24 hemopericardium 29.9 F9 F3 F2
25 alpha-1-antitrypsin deficiency 29.9 SERPINC1 F2 AFP
26 tricuspid valve insufficiency 29.9 F3 F2
27 stroke, ischemic 29.9 VKORC1 SERPINC1 F9 F7 F3 F2
28 thrombocytosis 29.8 SERPINC1 F3 F2
29 aortic valve insufficiency 29.8 F3 F2
30 intracranial embolism 29.8 SERPINC1 F3 F2
31 portal vein thrombosis 29.7 SERPINC1 F7 F2 AFP
32 hemophilia a 29.7 F9 F8 F7 F3
33 pulmonary embolism 29.7 SERPINC1 PROS1 F9 F8 F3 F2
34 purpura 29.6 SERPINC1 PROS1 F3 F2
35 post-thrombotic syndrome 29.6 SERPINC1 F8 F3 F2
36 arteriosclerosis 29.6 SERPINC1 MGP F3
37 aspiration pneumonia 29.6 F3 F2
38 cerebrovascular disease 29.6 VKORC1 F8 F7 F2
39 esophageal varix 29.6 SERPINC1 F3 F2 AFP
40 patent foramen ovale 29.5 SERPINC1 F3 F2
41 disseminated intravascular coagulation 29.5 SERPINC1 F9 F7 F3 F2
42 carotid artery thrombosis 29.5 SERPINC1 F3
43 cerebral palsy 29.4 SERPINC1 F7 F2 BGLAP
44 von willebrand's disease 29.4 F9 F8 F7 F3 F2
45 thrombophilia due to activated protein c resistance 29.4 SERPINC1 F8 F3 F2
46 cardiac tamponade 29.4 F9 F8 F7 F3 F2
47 retinal vascular occlusion 29.4 VKORC1 SERPINC1 F3 F2
48 retinal vein occlusion 29.4 VKORC1 SERPINC1 F3 F2
49 nephrotic syndrome 29.4 SERPINC1 F9 F3 F2
50 heart disease 29.3 VKORC1 SERPINC1 MGP F8 F7 F3

Comorbidity relations with Vitamin K Deficiency Bleeding via Phenotypic Disease Network (PDN):

Acute Cystitis Familial Atrial Fibrillation
Heart Disease

Graphical network of the top 20 diseases related to Vitamin K Deficiency Bleeding:

Diseases related to Vitamin K Deficiency Bleeding

Symptoms & Phenotypes for Vitamin K Deficiency Bleeding

MGI Mouse Phenotypes related to Vitamin K Deficiency Bleeding:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 F2 F3 F7 F9 GAS6 GGCX
2 homeostasis/metabolism MP:0005376 10 AFP BGLAP F2 F3 F7 F8
3 hematopoietic system MP:0005397 9.96 BGLAP F3 F8 F9 GAS6 GGCX
4 mortality/aging MP:0010768 9.77 AFP F2 F3 F7 F8 F9
5 muscle MP:0005369 9.1 F2 F3 MGP PROS1 SERPINC1 VKORC1

Drugs & Therapeutics for Vitamin K Deficiency Bleeding

Drugs for Vitamin K Deficiency Bleeding (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
# Name Status Phase Clinical Trials Cas Number PubChem Id
fluindione Approved, Investigational Phase 4 957-56-2
Phenindione Approved, Investigational Phase 4 83-12-5 4760
Edoxaban Approved Phase 4 480449-70-5
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Ticagrelor Approved Phase 4 274693-27-5 9871419
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Phenprocoumon Approved, Investigational Phase 4 435-97-2 9908 54680692
Thrombin Approved, Investigational Phase 4
Apixaban Approved Phase 4 503612-47-3 10182969
Protein C Approved Phase 4
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
Dalteparin Approved Phase 4 9005-49-6
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
Coumarin Experimental Phase 4 91-64-5 323
Dabigatran Investigational Phase 4 211914-51-1
17 Vitamin K 2 Phase 4
18 Vitamin K 1 Phase 4
19 Pharmaceutical Solutions Phase 4
20 Platelet Aggregation Inhibitors Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 Antirheumatic Agents Phase 4
23 Cyclooxygenase Inhibitors Phase 4
24 Anti-Inflammatory Agents Phase 4
25 Analgesics Phase 4
26 Antipyretics Phase 4
27 Anti-Inflammatory Agents, Non-Steroidal Phase 4
28 Antivitamins K Phase 4
29 Protamines Phase 4
30 Trace Elements Phase 4
31 Nutrients Phase 4
32 Micronutrients Phase 4
33 Hemostatics Phase 4
34 Antifibrinolytic Agents Phase 4
35 protein S Phase 4
36 Coagulants Phase 4
37 Calcium, Dietary Phase 4
38 Fibrinolytic Agents Phase 4
39 Heparin, Low-Molecular-Weight Phase 4
40 calcium heparin Phase 4
Calcium Nutraceutical Phase 4 7440-70-2 271
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
Iodine Approved, Investigational Phase 2, Phase 3 7553-56-2 807
tannic acid Approved Phase 3 1401-55-4
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
Acetazolamide Approved, Vet_approved Phase 3 59-66-5 1986
Povidone Approved Phase 2, Phase 3 9003-39-8 131751496
Povidone-iodine Approved Phase 2, Phase 3 25655-41-8
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
Prilocaine Approved Phase 2, Phase 3 721-50-6 4906

Interventional clinical trials:

(show top 50) (show all 205)
# Name Status NCT ID Phase Drugs
1 The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism. Unknown status NCT03129555 Phase 4 Dabigatran Etexilate Oral Capsule;Rivaroxaban Oral Tablet;Edoxaban Oral Tablet;Apixaban Oral Tablet
2 Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) Unknown status NCT03490994 Phase 4 Rivaroxaban;Warfarin + LMWH
3 A Prospective, Randomized Study of Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal at a Large Tertiary Care Medical Center Completed NCT03064035 Phase 4 4-factor prothrombin complex concentrate (4FPCC)
4 Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation Completed NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
5 Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients: A Prospective, Randomized Placebo-controlled Double Blind Trial Completed NCT02976246 Phase 4
6 The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease Completed NCT01235325 Phase 4
7 Anticoagulant Clinic-based Shared-care Versus Usual Cate Management of Vitamin K Antagonist Therapy : the Open, Randomized Multicenter Study Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
8 The Effect of Vitamin K Supplementation on Glucose Metabolism Completed NCT00960973 Phase 4 Menatetrenone;Placebo
9 Safety and Efficacy of Vitamin K Antagonists Versus Rivaroxaban in Hemodialysis Patients With Atrial Fibrillation: a Multicenter Randomized Controlled Trial Completed NCT03799822 Phase 4 Rivaroxaban 10 MG Oral Tablet;Vitamin K Antagonist - Drug
10 Effects of VITAmin K in Lessening Erythema Grade Associated to Injection Site Reactions in Patients Treated With PlegridY (VITALITY) Completed NCT03091569 Phase 4
11 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Completed NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
12 An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention Completed NCT02415400 Phase 4 Apixaban;vitamin K antagonist;Acetylsalicylic acid
13 The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial Completed NCT02610933 Phase 4 rivaroxaban
14 Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial) Completed NCT02066662 Phase 4 Rivaroxaban or Marcumar
15 Multicenter, Prospective Randomized Trial on the Use of Prothrombin Complex and Fresh Frozen Plasma in Patients With Intracerebral Hemorrhage Related to Vitamin K Antagonists Completed NCT00928915 Phase 4 Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)
16 A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion Completed NCT02100228 Phase 4 Apixaban;Parenteral heparin and/or oral Vitamin K antagonist
17 Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD Completed NCT02046460 Phase 4 Acetylsalicylic acid;Vitamin K antagonist
18 The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF) Recruiting NCT04437654 Phase 4 Anticoagulation group(Apixaban group)
19 The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF). Recruiting NCT03129490 Phase 4 Dabigatran Etexilate Oral Capsule;Rivaroxaban Oral Tablet;Edoxaban Oral Tablet;Apixaban Oral Tablet
20 Comparison of a Decreasing Dose of Daily Intravenous Vitamin K to a Single Dose Given as Standard of Care to an Historical Cohort in Subjects With Larger Burns Recruiting NCT03941535 Phase 4 Vitamin K
21 The Clinical Effect of Vitamin K Administration in Type 2 Diabetic Patients Recruiting NCT04285450 Phase 4
22 Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI) Recruiting NCT04437303 Phase 4 Continuation of oral anticoagulants;Interruption of oral anticoagulants
23 Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions - an Open, Multicenter Randomized Controlled Trial With Two Parallel Arms (1:1) Recruiting NCT02735902 Phase 4 Vitamin K antagonist or direct oral anticoagulant treatment;Aspirin
25 Study of the Benefit / Risk Ratio of Oral Anticoagulation in Hemodialysis Patients With Atrial Fibrillation Recruiting NCT02886962 Phase 4 Oral anticoagulation with vitamin K antagonists
26 Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG Recruiting NCT04045665 Phase 4 Antiplatelet-only strategy;Oral Anticoagulant plus background antiplatelet therapy
27 Randomized, Evaluation of Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement Not yet recruiting NCT04258488 Phase 4 Apixaban Oral Tablet;Vitamin K antagonist(warfarin)
28 AntiCoagulants and COGnition (ACCOG Trial): a Single-blind Randomized Controlled Trial Comparing the Neurocognitive Effects of Rivaroxaban Versus Vitamin K Antagonist Not yet recruiting NCT04073316 Phase 4 Rivaroxaban 20 MG;Warfarin
29 Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery, Compared With Fresh Frozen Plasma: Study Protocol for a Non-inferiority, Randomized Controlled Trial Not yet recruiting NCT04244981 Phase 4 Prothrombin Complex Concentrate, Human;Fresh Frozen Plasma
30 Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISE CONTROL) Terminated NCT00800137 Phase 4 low molecular weight heparin or unfractionated heparin;Warfarin or coumadin
31 Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin in Patients With Atrial Fibrillation and Mitral Stenosis Among Pakistani Population Withdrawn NCT03673605 Phase 4 Rivaroxaban 15 mg;Warfarin
32 The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Withdrawn NCT02885545 Phase 4 Continued therapy with the prescribed oral anticoagulant
33 A "Real-World", Randomized, Open-Label, Study on the Efficacy, Safety, and Tolerability of Tecarfarin (ATI-5923) a Novel Vitamin K Antagonist, Versus Warfarin in Subjects Requiring Chronic Anticoagulation Unknown status NCT02522221 Phase 3 Warfarin;tecarfarin
34 A Randomized, Double Blind Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation Unknown status NCT00691470 Phase 2, Phase 3 ATI-5923;Coumadin (warfarin)
35 An Open-label, Uncontrolled, Single-arm, Multicenter Phase IIIb Study to Assess the Efficacy and Safety of BE1116 in Japanese Subjects Receiving Vitamin K Antagonist Therapy With an Elevated INR and Either Acute Major Bleeding or a Requirement for Urgent Reversal of Vitamin K Antagonist Therapy for a Surgical or Invasive Medical Procedure Completed NCT02281201 Phase 3
36 Effects of Supplementation With Zinc and Other Micronutrients on the Health and Development of African Children Completed NCT00623857 Phase 3
37 Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement. Completed NCT02866175 Phase 3 Edoxaban;Clopidogrel;Prasugrel;Ticagrelor;Vitamin K antagonist
38 The Van Gogh-extension Trial, a Multicenter, International, Randomized, Double-blind, Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous SR34006 With Placebo in the Long-term Prevention of Symptomatic Venous Thromboembolism in Patients With Symptomatic Pulmonary Embolism or Deep-vein Thrombosis Who Completed 6 Months of Treatment With Vitamin K Antagonist or SR34006 Completed NCT00071279 Phase 3 SR34006 (idraparinux sodium) Injection
39 The AMADEUS Trial, A Multicenter, Randomized, Open-label, Assessor Blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Idraparinux (SR34006) With Adjusted-dose Oral Vitamin-K Antagonists in the Prevention of Thromboembolic Events in Patients With Atrial Fibrillation Completed NCT00070655 Phase 3 SR34006 (idraparinux sodium) Injection;vitamin K antagonist (warfarin or acenocoumarol) tablets
40 Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial Completed NCT00496769 Phase 3 Apixaban;Acetylsalicylic acid
41 Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification Completed NCT00183001 Phase 3 Vitamin K
42 Evaluation of the Clinical Use of Vitamin K Supplementation in Post-Menopausal Women With Osteopenia (ECKO Trial) Completed NCT00150969 Phase 3
43 An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Completed NCT01830543 Phase 3 rivaroxaban 2.5 mg;rivaroxaban 15 mg;rivaroxaban 10 mg;aspirin (ASA);vitamin K antagonist (VKA);clopidogrel;prasugrel;ticagrelor
44 A Multicentre, Multinational Study of Oral Vitamin K for the Treatment of Warfarin Associated Coagulopathy Completed NCT00143715 Phase 3 Phytonadione (Vitamin K1)
45 The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism Completed NCT00062803 Phase 3 SR34006;(LMW)heparin;Warfarin VKA;Acenocoumarol VKA
46 Vitamin K and Bone Turnover in Postmenopausal Women Completed NCT00062595 Phase 3 phylloquinone (K1);menatetranone (MK4)
47 Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT Completed NCT01130025 Phase 3 Warfarin;Innohep®
48 A Randomized, Open-label, Efficacy and Safety Study of Octaplex and Fresh Frozen Plasma (FFP) in Patients Under Vitamin K Antagonist Therapy With the Need for Urgent Surgery or Invasive Procedures Completed NCT00618098 Phase 3
49 A Multicentre Study of Low Dose Oral Vitamin K for INR Control in Patients Receiving Warfarin Completed NCT00990158 Phase 3 Phytonadione (Vitamin K1);Placebo
50 A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion Completed NCT01674647 Phase 3 Rivaroxaban (Xarelto, BAY59-7939);Vitamin K antagonist (VKA)

Search NIH Clinical Center for Vitamin K Deficiency Bleeding

Cochrane evidence based reviews: vitamin k deficiency

Genetic Tests for Vitamin K Deficiency Bleeding

Anatomical Context for Vitamin K Deficiency Bleeding

MalaCards organs/tissues related to Vitamin K Deficiency Bleeding:

Bone, Liver, Breast, Kidney, Brain, Skin, Prostate

Publications for Vitamin K Deficiency Bleeding

Articles related to Vitamin K Deficiency Bleeding:

(show top 50) (show all 1152)
# Title Authors PMID Year
Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status. 42
33308246 2020
The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis. 42
33375495 2020
Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study. 42
33374341 2020
Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging? 54 61
19692494 2009
Prevalence of vitamin K and vitamin D deficiency in patients with hepatobiliary and pancreatic disorders. 54 61
19854384 2009
Prevalence of subclinical vitamin K deficiency in cholestatic liver disease. 61 54
19502999 2009
Coagulation meets calcification: the vitamin K system. 61 54
19363777 2009
Extremes in vitamin K status of bone are related to bone ultrasound properties in children with juvenile idiopathic arthritis. 54 61
18578975 2008
The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. 54 61
18401181 2008
Coagulopathy in liver disease. 54 61
18221607 2007
Justifying the clinical use of fresh frozen plasma - an audit. 61 54
17462177 2007
Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. 61 54
16807654 2006
A case of spontaneous regression of hepatocellular carcinoma with multiple lung metastases. 54 61
16715676 2006
Role of vitamin K2 in the treatment of postmenopausal osteoporosis. 61 54
18690918 2006
Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma. 54 61
16425352 2005
Biliary lithiasis in early pregnancy and abnormal development of facial and distal limb bones (Binder syndrome): a possible role for vitamin K deficiency. 61 54
15751048 2005
Prevalence and clinical associations of prolonged prothrombin time in adult untreated coeliac disease. 61 54
15075998 2004
Effects of vitamin K2 on osteoporosis. 54 61
15320745 2004
Echis time, under-carboxylated prothrombin and vitamin K status in intensive care patients. 61 54
14641145 2003
Vitamin K and bone health. 61 54
15018483 2003
Dietary phylloquinone depletion and repletion in older women. 61 54
12888638 2003
Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. 61 54
11994567 2002
Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency. 61 54
11846334 2001
Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. 54 61
11410932 2001
Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? 54 61
11247890 2001
Vitamin K deficiency in diarrhoea. 54 61
11338219 2001
Are breast-fed infants vitamin K deficient? 61 54
11787707 2001
Use of oral anticoagulants in older patients. 54 61
10939307 2000
Severe acquired vitamin K deficiency: a hypothesis for rapid response to therapy. 61 54
10870812 2000
Systemic causes of excessive uterine bleeding. 61 54
10513767 1999
Bioavailability of phylloquinone from an intravenous lipid emulsion. 54 61
9537619 1998
[How do we manage the hemorrhagic risk on hypovitaminosis K and treatments with antivitamin K]. 54 61
9750673 1998
Plasma vitamin K1 level is decreased in primary biliary cirrhosis. 54 61
9362192 1997
Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements. 54 61
8989344 1997
The effect of combined antenatal vitamin K and phenobarbital therapy on umbilical blood coagulation studies in infants less than 34 weeks' gestation. 54 61
7501353 1995
Vitamin K deficiency. 54 61
7886607 1993
Evidence of vitamin K deficiency in cord blood. 61 54
7886551 1993
[Intrahepatic cholestasis in pregnancy. The hepatologist's point of view]. 61 54
8228018 1993
Hemolytic uremic syndrome complicated by vitamin K deficiency. 54 61
2069228 1991
Prediction of vitamin K response using the Echis time and Echis-prothrombin time ratio. 54 61
2096486 1990
Chemical modification of gamma-carboxyglutamic acid residues in prothrombin elicits a conformation similar to that of abnormal (des-gamma-carboxy)prothrombin. 61 54
2277030 1990
An Unusual Presentation of Hemorrhagic Disease in an Infant: A Probable Case of Abetalipoproteinemia. 61
32433446 2021
The challenge to define the optimal prophylactic regimen for vitamin K deficiency bleeding in infants. 61
32892390 2021
The ViKTORIES trial: a randomised, double-blind, placebo-controlled trial of vitamin K supplementation to improve vascular health in kidney transplant recipients. 61
33742520 2021
Statins, vascular calcification, and vitamin K-dependent proteins: Is there a relation? 61
33634559 2021
Retinal hemorrhage and bleeding disorders in children: A review. 61
33401159 2021
Vitamins K and D deficiency in severe motor and intellectually disabled patients. 61
33139126 2021
The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study. 61
33461606 2021
Pediatric Emergency Medicine Simulation Curriculum: Vitamin K Deficiency in the Newborn. 61
33511273 2021
Dietary vitamin K is remodeled by gut microbiota and influences community composition. 61
33651646 2021

Variations for Vitamin K Deficiency Bleeding

Expression for Vitamin K Deficiency Bleeding

Search GEO for disease gene expression data for Vitamin K Deficiency Bleeding.

Pathways for Vitamin K Deficiency Bleeding

Pathways related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
13.43 PROS1 GGCX GAS6 F9 F8 F7
Show member pathways
13.05 SERPINC1 PROS1 GAS6 F9 F8 F7
Show member pathways
12.6 SERPINC1 PROS1 F9 F8 F7 F3
Show member pathways
Show member pathways
11.88 PROS1 GAS6 F2
6 11.86 SERPINC1 PROS1 F9 F8 F7 F3
Show member pathways
Show member pathways
11.53 PROS1 GGCX GAS6 F9 F7 F2

GO Terms for Vitamin K Deficiency Bleeding

Cellular components related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.96 SERPINC1 PROS1 GAS6 F9 F8 F7
2 extracellular region GO:0005576 9.9 SERPINC1 PROS1 MGP GAS6 F9 F8
3 collagen-containing extracellular matrix GO:0062023 9.8 SERPINC1 MGP F9 F7 F3 F2
4 blood microparticle GO:0072562 9.61 SERPINC1 PROS1 F2
5 platelet alpha granule lumen GO:0031093 9.58 PROS1 GAS6 F8
6 Golgi lumen GO:0005796 9.43 PROS1 GAS6 F9 F7 F2 BGLAP
7 serine-type peptidase complex GO:1905286 9.37 F7 F3
8 endoplasmic reticulum lumen GO:0005788 9.23 SERPINC1 GAS6 F9 F8 F7 F2

Biological processes related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.8 SERPINC1 GAS6 F2 AFP
2 positive regulation of protein kinase B signaling GO:0051897 9.75 GAS6 F7 F3
3 response to organic cyclic compound GO:0014070 9.72 VKORC1 F7 BGLAP
4 platelet degranulation GO:0002576 9.71 PROS1 GAS6 F8
5 ER to Golgi vesicle-mediated transport GO:0006888 9.7 PROS1 GAS6 F9 F8 F7 F2
6 regulation of bone mineralization GO:0030500 9.57 MGP BGLAP
7 fibrinolysis GO:0042730 9.56 PROS1 F2
8 blood coagulation, intrinsic pathway GO:0007597 9.54 F9 F8 F2
9 positive regulation of blood coagulation GO:0030194 9.52 F7 F2
10 positive regulation of positive chemotaxis GO:0050927 9.51 F7 F3
11 regulation of blood coagulation GO:0030193 9.5 VKORC1 SERPINC1 F2
12 hemostasis GO:0007599 9.5 SERPINC1 PROS1 F9 F8 F7 F3
13 vitamin K metabolic process GO:0042373 9.48 VKORC1L1 VKORC1
14 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.46 F7 F3
15 blood coagulation, extrinsic pathway GO:0007598 9.43 F7 F3
16 peptidyl-glutamic acid carboxylation GO:0017187 9.43 VKORC1L1 VKORC1 GGCX
17 response to vitamin K GO:0032571 9.4 F7 BGLAP
18 blood coagulation GO:0007596 9.32 VKORC1 SERPINC1 PROS1 GGCX GAS6 F9

Molecular functions related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.56 F9 F7 F3 F2
2 serine-type peptidase activity GO:0008236 9.54 F9 F7 F2
3 quinone binding GO:0048038 9.32 VKORC1L1 VKORC1
4 calcium ion binding GO:0005509 9.17 PROS1 MGP GAS6 F9 F7 F2
5 vitamin-K-epoxide reductase (warfarin-sensitive) activity GO:0047057 9.16 VKORC1L1 VKORC1
6 structural constituent of bone GO:0008147 8.96 MGP BGLAP

Sources for Vitamin K Deficiency Bleeding

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....